AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 271 min read$INDV

Anderson Woodrow D purchased $54K of INDV

Anderson Woodrow D (Chief Accounting Officer) purchased 1,500 shares of Indivior Pharmaceuticals, Inc. (INDV) at $35.69 on 2026-08-27.

Original reporting
SEC EDGAR · Anderson Woodrow D
Published Aug 27, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INDV
Neutral
medium confidence
Mentioned
$INDV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INDVNeutralLow
01

Why it matters

The purchase modestly raises the insider's stake, but the amount is too small to drive price action.

02

Market read

Insider purchase of $53K is a low‑impact event for INDV.

03

What to watch

Potential upcoming regulatory or product milestones for INDV not disclosed in this filing.

Relevance 4/10Novelty 5/10Timing: same-day filing on 2026-08-27

Background

Form 4 filings disclose insider transactions; market participants monitor them for signals.

Company-level read

Ticker impact

$INDVNeutralMedium confidence
Context

Chief Accounting Officer purchased 1,500 shares for $53,535, increasing holdings to 27,638 shares.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

The purchase size is modest relative to market cap and typical trading volume, reducing actionable significance.

Market effects

Sector

No broader sector impact; the transaction is company‑specific.

Regional

Limited to investors tracking INDV.

Global

Negligible.

Counterpoint

What could challenge this read

The buy could be a routine portfolio adjustment rather than a confidence signal.

Key entities

  • Officer
    Anderson Woodrow D

    Chief Accounting Officer of Indivior Pharmaceuticals, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INDV insider trading history →

Related articles

SEP 25
$INDVMed

Indivior ends PAM drug collab with Addex ahead of Supernus merger

Indivior Pharmaceuticals ended its collaboration with Addex Therapeutics on positive allosteric modulators (PAMs) ahead of its merger with Supernus. Indivior returned all PAM assets to Addex, which plans to explore strategic options for advancing its GABAB receptor portfolio. Indivior had previously discontinued another collaboration in April. The merger with Supernus is expected to create a new CNS-focused biopharma.

fiercebiotech.com2 min
AUG 28
$INDVHighAI 9/10

Indivior Pharmaceuticals (INDV) plans $1B payout tied to Supernus merger

Indivior Pharmaceuticals (INDV) filed an S-4 for an all-stock merger with Supernus Pharmaceuticals (SUPN). Each Supernus share will convert to 1.5401 Indivior shares. Indivior plans a $1B special dividend, contingent on merger completion, with a $650M loan to fund it. Post-merger, Indivior will rename to Supernus and trade under SUPN. The deal is expected to close in Q4 2026, subject to approvals.

stocktitan.net3 min
AUG 10
$SUPNMed

Biotech funding rises 75% year-over-year, Braveheart surges

Macquarie said global biotech funding for the year through Aug. 7 rose 75% YoY, driven by IPOs up 235% and follow-ons up 138%. The XBI biotech index gained 7% in the week to Aug. 7. Braveheart Bio’s upsized IPO raised $382.5M and shares jumped 66%. Curium agreed to buy Lantheus for up to $8B, and Supernus and Indivior plan an all-stock merger.

investing.com6 min